Insmed Inc
$ 177.88
0.26%
26 Dec - close price
- Market Cap 37,937,086,000 USD
- Current Price $ 177.88
- High / Low $ 179.44 / 176.67
- Stock P/E N/A
- Book Value 4.45
- EPS -6.19
- Next Earning Report 2026-02-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -1.66 %
- 52 Week High 212.75
- 52 Week Low 60.40
About
Insmed Inc. is a biopharmaceutical company headquartered in Bridgewater, New Jersey, dedicated to developing innovative therapies for rare and serious diseases, with a particular emphasis on pulmonary and infectious conditions. The company’s flagship product, ARIKAYCE, provides a treatment option for patients with treatment-refractory Mycobacterium avium complex lung disease, underscoring Insmed's focus on addressing significant unmet medical needs in the market. With a strong pipeline and a commitment to research and development, Insmed is strategically positioned for substantial growth and innovation, aiming to enhance health outcomes for patients suffering from rare diseases.
Analyst Target Price
$214.94
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-08-07 | 2025-05-07 | 2025-02-20 | 2024-10-31 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-10-26 | 2023-08-03 | 2023-05-04 | 2023-02-23 |
| Reported EPS | -1.75 | -1.7 | -1.42 | -1.32 | -1.27 | -1.94 | -1.06 | -1.28 | -1.11 | -1.78 | -1.17 | -1.21 |
| Estimated EPS | -1.32 | -1.3 | -1.2 | -1.23 | -1.22 | -1.27 | -1.23 | -1.15 | -1.13 | -1.13 | -1.11 | -1.04 |
| Surprise | -0.43 | -0.4 | -0.22 | -0.09 | -0.05 | -0.67 | 0.17 | -0.13 | 0.02 | -0.65 | -0.06 | -0.17 |
| Surprise Percentage | -32.5758% | -30.7692% | -18.3333% | -7.3171% | -4.0984% | -52.7559% | 13.8211% | -11.3043% | 1.7699% | -57.5221% | -5.4054% | -16.3462% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INSM
2025-12-28 16:09:25
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Insmed Incorporated (INSM) following a significant stock price drop. This drop occurred after Insmed announced that its Phase 2b BiRCh study for brensocatib failed to meet its primary or secondary efficacy endpoints, leading to the discontinuation of the drug's development. The firm is encouraging stockholders who purchased Insmed securities to contact them to learn more about the investigation and assist with potential class action claims.
2025-12-28 15:09:25
Pomerantz LLP is investigating potential claims against Insmed Incorporated (NASDAQ: INSM) following a significant drop in its stock price. This investigation comes after Insmed announced that its Phase 2b BiRCh study for brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) failed to meet primary or secondary efficacy endpoints, leading to the discontinuation of the drug's development. On this news, Insmed's stock fell 16.08%, prompting the law firm to investigate potential securities fraud or unlawful business practices.
2025-12-27 19:09:50
Pomerantz LLP is investigating potential securities fraud claims against Insmed Incorporated (NASDAQ: INSM) following a significant stock drop. The investigation comes after Insmed announced that its Phase 2b BiRCh study of brensocatib failed to meet its primary or secondary efficacy endpoints, leading the company to discontinue its development. Insmed's stock price subsequently fell by over 16%.
2025-12-27 12:09:50
Rice Hall James & Associates LLC has reduced its stake in Insmed, Inc. ($INSM) by 8.2%, selling 7,103 shares and now holding 79,667 shares valued at $11.47 million. Several corporate insiders have also sold Insmed shares in recent months, totaling over $30 million. Despite these sales, Wall Street analysts maintain a "Moderate Buy" rating for Insmed, with an average price target of $205.41.
2025-12-27 09:09:50
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Insmed Incorporated (NASDAQ:INSM) following the company's announcement that its Phase 2b BiRCh study of brensocatib failed to meet its primary or secondary efficacy endpoints. This led to Insmed discontinuing the drug's development and experiencing a significant stock price drop. The firm encourages affected investors to contact them to learn more about potential claims.
2025-12-27 09:09:25
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Insmed Incorporated (INSM) following a significant drop in its stock price. This comes after Insmed announced that its Phase 2b BiRCh study of brensocatib failed to meet its primary and secondary efficacy endpoints, leading to the discontinuation of the drug's development. The firm is encouraging stockholders who purchased Insmed securities to join the investigation.
